Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.72 |
| ▸ | DGKA | P23743 | 1/20 | 0.72 |
| ▸ | HTR2C | P28335 | 1/20 | 0.67 |
| ▸ | RAD52 | P43351 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.59 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.59 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.59 |
| ▸ | FAAH | O00519 | 1/20 | 0.58 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.58 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 3/20 | 0.53 |
| ▸ | PAM | P19021 | 2/20 | 0.53 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9511621 | 1.00 | NAAA (0.72) | NAAADGKAHTR2CRAD52NPSR1 | |
| SCHEMBL334051 | 1.00 | NAAA (0.72) | NAAADGKAHTR2CRAD52NPSR1 | |
| SCHEMBL1091514 | 1.00 | NAAA (0.72) | NAAADGKAHTR2CRAD52NPSR1 | |
| SCHEMBL333278 | 1.00 | NAAA (0.72) | NAAADGKAHTR2CRAD52NPSR1 | |
| SCHEMBL21044706 | 1.00 | NAAA (0.72) | NAAADGKAHTR2CRAD52NPSR1 | |
| SCHEMBL21044646 | 1.00 | NAAA (0.72) | NAAADGKAHTR2CRAD52NPSR1 | |
| SCHEMBL10149466 | 1.00 | NAAA (0.72) | NAAADGKAHTR2CRAD52NPSR1 | |
| SCHEMBL128168 | 1.00 | NAAA (0.72) | NAAADGKAHTR2CRAD52NPSR1 | |
| SCHEMBL1171560 | 1.00 | NAAA (0.72) | NAAADGKAHTR2CRAD52NPSR1 | |
| SCHEMBL963961 | 1.00 | NAAA (0.72) | NAAADGKAHTR2CRAD52NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747001-A2 | SILICA CAPSULES | The Procter & Gamble Company (US) | 2026-05-27 | — | — | EP | disclosed |
| US-12571261-B2 | Pulsed power drilling with multiple selective drilling fluids | HALLIBURTON ENERGY SERVICES, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20260008793-A1 | IONIZABLE CATIONIC LIPIDS INCORPORATING SILICON | ALDEXCHEM KFT (HU) | 2026-01-08 | — | — | US | disclosed |
| US-12478942-B2 | Methods of making capsules | THE PROCTER & GAMBLE COMPANY (US) | 2025-11-25 | — | — | US | disclosed |
| US-20250250863-A1 | PULSED POWER DRILLING WITH MULTIPLE SELECTIVE DRILLING FLUIDS | HALLIBURTON ENERGY SERVICES, INC. | 2025-08-07 | — | — | US | disclosed |
| EP-3955890-B1 | CAPSULES | PROCTER & GAMBLE (US) | 2025-07-16 | — | — | EP | disclosed |
| US-12343696-B2 | Capsules | THE PROCTER & GAMBLE COMPANY (US) | 2025-07-01 | — | — | US | disclosed |
| EP-4562021-A2 | IONIZABLE CATIONIC LIPIDS INCORPORATING SILICON | AldexChem Kft. (HU) | 2025-06-04 | — | — | EP | disclosed |
| CN-120001297-A | Capsule | 宝洁公司 | 2025-05-16 | — | — | CN | disclosed |
| US-20250136349-A1 | CONTAINER AND METHOD FOR PRESERVING OR TRANSPORTING BIOLOGICAL MATERIALS | UNITED THERAPEUTICS CORPORATION (US) | 2025-05-01 | — | — | US | disclosed |
| US-6569449-B1 | For treatment of eating disorders, narcotic dependence and alcoholism. | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2003-05-27 | — | — | US | disclosed |
| US-6093753-A | CURABLE COMPOSITION COMPRISING A CATIONIC POLYMERIZABLE COMPOUND WHICH IS AN ALICYCLIC EPOXY COMPOUND OR A VINYL ETHER COMPOUND AND A CATIONIC POLYMERIZATION INITIATOR; PAINTS, ADHESIVES, INKS, PHOTORESISTS | NIPPON SODA CO., LTD. (JP) | 2000-07-25 | — | — | US | disclosed |
| EP-0846681-A1 | NOVEL SULFONIUM SALT COMPOUNDS, POLYMERIZATION INITIATOR, CURABLE COMPOSITION, AND CURING METHOD | NIPPON SODA CO., LTD. (JP) | 1998-06-10 | — | — | EP | disclosed |
| EP-0368406-B1 | COMPOSITIONS FOR THE TRANSDERMAL DELIVERY OF PHARMACEUTICAL ACTIVES | Norwich Eaton Pharmaceuticals, Inc. (US) | 1993-07-28 | — | — | EP | disclosed |
| US-5149538-A | Misuse-resistive transdermal opioid dosage form | WARNER-LAMBERT COMPANY (US) | 1992-09-22 | — | — | US | disclosed |
| US-5026556-A | Buprenorphine in carrier comprises lower alkyl diols or triols and a polar lipid | NORWICH EATON PHARMACEUTICALS, INC. (US) | 1991-06-25 | — | — | US | disclosed |
| EP-0368409-A2 | Compositions for the transdermal delivery of buprenorphine salts | Norwich Eaton Pharmaceuticals, Inc. (US) | 1990-05-16 | — | — | EP | disclosed |
| EP-0368406-A2 | Compositions for the transdermal delivery of pharmaceutical actives | Norwich Eaton Pharmaceuticals, Inc. (US) | 1990-05-16 | — | — | EP | disclosed |
| US-4910124-A | Pyrazoloazole coupler | FUJI PHOTO FILM CO., LTD. (JP) | 1990-03-20 | — | — | US | disclosed |
| US-4472338-A | MIXING WITH NUCLEATING AGENT AND DISPERSANT | BAYER AKTIENGESELLSCHAFT (DE) | 1984-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260008793-A1 | IONIZABLE CATIONIC LIPIDS INCORPORATING SILICON | SGMS1, SGMS2, AGO2 | NAAA 3002/4885DGKA 688/4885HTR2C 4682/4885 |
| US-12478942-B2 | Methods of making capsules | FUT6, FUT5, LIPA | NAAA 523/4885DGKA 4492/4885HTR2C 687/4885 |
| US-12571261-B2 | Pulsed power drilling with multiple selective drilling fluids | ROCK1, PIEZO1, DNM1 | NAAA 3969/4885DGKA 442/4885HTR2C 1984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.